CD274 and breast carcinoma: In contrast, for breast cancer cells, binding of all three therapeutic PD‐L1 antibodies favoured glycosylated PD‐L1 over the non‐glycosylated protein, and DL showed the highest affinity (Benicky et al., 2021).